Mersana Therapeutics (MRSN)

• Market cap: $143M
• 1 day: 0.07%
• 5 days: 2.51%
• 1 month: 3.21%
• 3 months: 296.81%
• 6 months: 201.16%
• Year to date: -18.26%
• 1 year: -44.71%
• 5 years: -95.36%
• 10 years: -91.83%
• Sector: Healthcare
• Industry: Biotechnology

About: Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.

Employees: 102